Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis

Jun Yang1, Shuqin Chen, Xuan Huang

  • 1Department of Biochemistry, Zhongshan Medical School of Sun Yat-sen University, Guangzhou, Guangdong Province, China.

Insights

Pigment epithelium-derived factor (PEDF) shows promise in treating cervical cancer by inhibiting tumor growth and neovascularization. This study demonstrates PEDF

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cervical cancer is a leading cause of death in women, driven by angiogenesis.
  • Pigment epithelium-derived factor (PEDF) is an endogenous angiogenesis inhibitor with demonstrated anti-tumor effects.
  • The role of PEDF in cervical cancer treatment remains underexplored.

Purpose of the Study:

  • To investigate the therapeutic potential of recombinant PEDF in cervical carcinoma.
  • To evaluate PEDF's effect on tumor neovascularization and growth.
  • To elucidate the underlying molecular mechanisms of PEDF's action.

Main Methods:

  • Assessed PEDF expression in human cervical carcinoma tissues.
  • Administered intraperitoneal recombinant PEDF to xenografted cervical carcinoma mouse models.
  • Quantified tumor growth, microvessel density, and endothelial cell apoptosis.
  • Investigated PEDF's direct effects on Hela cells and its impact on VEGF and HIF-1α expression.

Main Results:

  • PEDF was found to be downregulated in cervical carcinoma tissues.
  • PEDF treatment significantly suppressed tumor growth by 68% and reduced microvessel density.
  • PEDF inhibited endothelial cell proliferation and induced apoptosis, but did not directly affect Hela cells.
  • PEDF downregulated VEGF expression in Hela cells by inhibiting HIF-1α.

Conclusions:

  • PEDF exhibits significant anti-angiogenic and anti-tumor effects in cervical carcinoma models.
  • PEDF suppresses cervical cancer growth primarily by inhibiting angiogenesis, not through direct cytotoxicity.
  • The mechanism involves downregulation of VEGF via HIF-1α, reducing tumor neovascularization.